Treatment of Aggressive Central Giant Cell Granuloma

Phase 3

• Conditions: central giant cell granuloma.; Giant cell granuloma, central

• Registration Number: IRCT2015011820711N1
• Lead Sponsor: Shiraz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

Inclusion Criteria:
•clinical and histopathological diagnosis of aggressive CGCG based on accepted criteria established by chuong etal; normal level of calcitonin and serum Parathyroid hormone(PTH) Patients; ;of both sexes between 13 to 30 year's old Patients who gave written informed consent Patients who were willing for evaluation in the fallow up session; Primary size of the lesion should be more than 5 cm in CBCT;

Exclusion Criteria

•Participants demonstrating a systemic disease which affects bone healing;brown tumor ;pregnancy ; recently corticosteroid therapy ; previous surgical intervention for CGCG or refused study enrollment and whom they could not continue the study for private or social reasons were excluded from the study sample.

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
•Relief sign &symptom and clinical features [ Time Frame: 5 years ] [ Designated as safety issue: Yes ]. Timepoint: 5 years. Method of measurement: Recurrence lesions were documented by clinical and radiographical examinations and proved by histopathological evaluation.

Secondary Outcome Measures

Name	Time	Method
•recurrence rate of CGCG [ Time Frame: 5 years ] [ Designated as safety issue: Yes ]. Timepoint: 5 years ]. Method of measurement: Recurrence lesions were documented by clinical and radiographical examinations and proved by histopathological evaluation.